A newer GLP-1 receptor agonist, tirzepatide, demonstrates weight loss as high as 20% change in body weight compared with 3% in the placebo group in a RCT
In addition to quieting that food noise, these types of weight loss medications can actually reduce heart disease, "that might be independent of weight loss," in addition to "improvements in heart function and functional status in individuals with heart failure." The medication is also currently being studied for how it can target symptoms of kidney disease and Alzheimer's
* Despite the ability of #GLP-1s to produce significant #weightreduction and related health benefits, challenges such as GI side effects, risk of nutrient inadequacies, #loss of #muscle and #bone mass, high costs, frequent discontinuation, and #weightregain limit the use of these drugs for #longterm #success in individuals and populations
Managing stress through structured physical activity, consistent routines, and intentional recovery is not a soft lifestyle recommendation
Occasional exposure to room temperature is not always harmful
